Obstetrics Research Today is a free monthly online journal that collates and summarizes the latest research about Obstetrics, including details on caesarean delivery, child birth, labour.
Effects of duration of cryo-storage of mouse oocytes on cryo-survival, fertilization and embryonic development following vitrification.
Yan J, Suzuki J, Yu XM, Qiao J, Kan FW, Chian RC
Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.
PURPOSE: To investigate the effects of cryo-storage duration in liquid nitrogen on oocyte cryo-survival, fertilization and embryonic development following vitrification and warming. METHODS: Mature mouse oocytes were vitrified with McGill Cryoleaf and stored in liquid nitrogen for a period of 8-10 days, 90-92 days and 180-182 days, respectively. After warming, the survived oocytes were inseminated by intracytoplasmic sperm injection (ICSI) and cultured for 120 h. The rates of oocyte cryo-survival, cleavage and embryonic development were compared. RESULT(S): The oocyte cryo-survival rate declined following cryo-storage duration for 180-182 days (90.4 ± 7.9%) compared to that of the other two groups (97.4 ± 3.0% and 98.0 ± 3.3%). The fertilization rate in the group of 180-182 days (66.6 ± 22.0%) was also significantly reduced (P < 0.05) compared with the groups of 8-10 days (92.2 ± 10.8%) and 90-92 days (94.7 ± 9.1%). In addition, the number of embryos developed to the blastocyst stage declined significantly (P < 0.05) following long cryo-storage duration (72.1 ± 8.2%, 25.2 ± 3.8% and 5.5 ± 13.6%, respectively). CONCLUSION(S): The cryo-survival, fertilization rate and embryonic development of mouse oocytes are affected significantly, in an adverse manner, by the cryo-storage duration in liquid nitrogen.
Published 16 May 2011 in J Assist Reprod Genet.
Articles on Obstetrics published 16 May 2011:
Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J Assist Reprod Genet.
PURPOSE: To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC). METHODS: The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment. RESULTS: AMH and AFC had a stronger correlation with the total number ... [Abstract] [Full-text]
PURPOSE: To investigate the association between the UBR2 gene and the risk of azoospermia caused by meiotic arrest. METHODS: Mutational analysis of the UBR2 gene was performed using DNA from 30 patients with azoospermia by meiotic arrest to 80 normal controls. RESULTS: The genotypic and allelic frequencies of c.1,066A>T variant were significantly higher in patient than control groups (p < 0.001). CONCLUSION: The c.1,066A>T variant in the UBR2 gene is associated with increased ... [Abstract] [Full-text]
Müllerian inhibiting substance (MIS), also known as anti-Müllerian hormone (AMH), is a member of the transforming growth factor-β (TGF-β) superfamily that plays an important role in the mesenchymal-epithelial interaction, cell growth and proliferation, extracellular matrix production and tissue remodeling. Previously, we demonstrated that MIS suppressed ovarian cancer cell growth and suggested large-scale genetic elements that could be responsible for anti-neoplastic effects of MIS on ... [Abstract] [Full-text]
Efficacy, safety, and patient acceptability of the Essure™ procedure. Patient Prefer Adherence, 5: 207-12.
The Essure™ system for permanent contraception was developed as a less invasive method of female sterilization. Placement of the Essure™ coil involves a hysteroscopic transcervical technique. This procedure can be done in a variety of settings and with a range of anesthetic options. More than eight years have passed since the US Food and Drug Administration approval of Essure™. Much research has been done to evaluate placement success, adverse outcomes, satisfaction, pain, and the ... [Abstract] [Full-text]
Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int J STD AIDS, 22(5): 294-5.
The data on the use of tipranavir and enfuvirtide in pregnancy are very limited. We performed a pharmacokinetic profile in a pregnant woman with multidrug-resistant HIV-1 infection at 37 weeks gestation. Tipranavir levels were in the therapeutic range and the cord blood concentration at delivery was relatively high when compared with other protease inhibitors. No enfuvirtide was detected in the fetal compartment. Tipranavir and enfuvirtide were successfully used in pregnancy, but possible ... [Abstract] [Full-text]
Abstract The GATA family of transcription factors are critical determinants of cell differentiation as well as regulation of adult gene expression throughout the reproductive axis. Within the anterior pituitary gland, GATA factors have been shown to increase glycoprotein α-subunit gene promoter activity; however, nothing has been known about the impact of these factors on expression of the gonadotropin β-subunits. In the current studies, we demonstrate expression of both GATA2 and GATA4 in ... [Abstract] [Full-text]
OBJECTIVE: To estimate the influence of oxytocin infusion on operative blood loss and glycine deficit during hysteroscopic transcervical endometrial resection (TCRE) for abnormal uterine bleeding (AUB). DESIGN: Prospective, randomized, placebo-controlled study (Canadian Task Force classification I). SETTING: Tertiary Care University Hospital. PATIENTS: Forty-eight women with abnormal uterine bleeding that was unresponsive to conservative medical management were randomly assigned to undergo ... [Abstract] [Full-text]
Vaginal cancer. Crit Rev Oncol Hematol.
Because of the low incidence of vaginal cancer, phase III trials have not been carried out and current guidelines have been drawn on retrospective studies. This state of affairs explains the variety of treatments to which women affected by this disease are subjected to. In this article, we report the current results achieved by different therapeutic strategies. The primary treatment options in Stage I vaginal carcinoma are surgery and/or radiotherapy. For a small tumor, a wide excision can be ... [Abstract] [Full-text]
© 2005-2013 Obstetrics Research Today. All Rights Reserved.